A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03898791 |
|
Recruitment Status :
Completed
First Posted : April 2, 2019
Last Update Posted : August 5, 2021
|
Sponsor:
Eli Lilly and Company
Information provided by (Responsible Party):
Eli Lilly and Company
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | June 2, 2020 |
| Actual Study Completion Date : | March 30, 2021 |